Wakamoto Pharmaceutical Co., Ltd. (4512) AI Stock Analysis

• Market Cap: ¥10.41B
• Dividend Yield: 1%
• Average Volume (3M): 112.55K
• Price to Earnings (P/E): 160.0
• Beta (1Y): 0.29
• Revenue Growth: 4.00%
• EPS Growth: -933.04%
• Country: JP
• Employees: 403
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -3.12
• Shares Outstanding: 34,838,326
• 10 Day Avg. Volume: 68,650
• 30 Day Avg. Volume: 112,553
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥307.00
• Price Target Upside: 3.02% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 52 Neutral
• Price Target: ¥307.00 ▲(3.02% Upside)

The overall stock score of 52 reflects a mixed financial performance with strong balance sheet stability but declining profitability and cash flow challenges. Technical indicators are neutral, and valuation metrics suggest caution due to negative earnings. The absence of earnings call and corporate events data limits further insights.

Wakamoto Pharmaceutical Co., Ltd. Business Overview & Revenue Model

Company Description

Wakamoto Pharmaceutical Co., Ltd. manufactures and sells ethical and non-prescription drugs in Japan. The company offers Strong Wakamoto, a gastrointestinal drug for digestion, intestinal regulation, and nutritional supplementation. It also provides AVANTBISE oral tablets, a supplement of bacteria to restore the balance of oral flora; and medicated toothpaste. The company was formerly known as Society for Nutrition and Raising Children Co., Ltd. and changed its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943. Wakamoto Pharmaceutical Co., Ltd. was founded in 1929 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Wakamoto Pharmaceutical Co., Ltd. generates revenue through the sale of its pharmaceutical and healthcare products. The company's key revenue streams include over-the-counter medications and nutritional supplements sold to consumers through retail channels. Additionally, prescription drugs contribute to their earnings, distributed through healthcare providers and hospitals. The company may also benefit from partnerships or collaborations with other pharmaceutical companies for research and development, manufacturing, or distribution, although specific partnership details are not available.

Wakamoto Pharmaceutical Co., Ltd. Financial Statement Overview

Summary

Wakamoto Pharmaceutical Co., Ltd. demonstrates a mixed financial performance. The strong balance sheet with a robust equity position and low debt-to-equity ratio is overshadowed by declining net income and negative cash flows, indicating inefficiencies in profitability and cash management.

Income Statement

The company faces fluctuating revenue trends with a slight increase from 2024 to 2025 but a decline over the long term. Gross profit margin remains stable but with decreasing net income, leading to declining net profit margins. Despite improvement in EBITDA margin, the EBIT margin remains negative, indicating operating inefficiency.

Balance Sheet

The balance sheet shows a robust equity position with a low debt-to-equity ratio, highlighting financial stability. However, the return on equity is diminishing due to declining net income. The equity ratio remains healthy, reflecting reliable asset management.

Cash Flow

Cash flow analysis indicates challenges with negative operating cash flow and free cash flow, raising concerns about cash management. The operating cash flow to net income and free cash flow to net income ratios suggest inefficiencies in converting profit to cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.98B	7.79B	7.74B	8.66B	8.38B	8.89B
Gross Profit	3.75B	3.62B	3.54B	4.11B	4.36B	4.49B
EBITDA	397.01M	438.68M	504.84M	575.81M	755.52M	-218.12M
Net Income	-177.67M	64.44M	108.96M	138.26M	238.54M	-601.86M
Balance Sheet
Total Assets	15.25B	15.00B	15.42B	15.71B	14.95B	14.57B
Cash, Cash Equivalents and Short-Term Investments	3.56B	2.95B	3.66B	3.88B	3.23B	2.84B
Total Debt	100.00M	100.00M	130.73M	137.79M	129.14M	171.20M
Total Liabilities	3.55B	3.39B	3.39B	3.80B	3.47B	3.19B
Stockholders Equity	11.70B	11.61B	12.03B	11.91B	11.48B	11.39B
Cash Flow
Free Cash Flow	820.56M	-1.04B	-663.02M	420.76M	-28.97M	-318.82M
Operating Cash Flow	820.56M	-592.45M	-107.34M	631.92M	339.17M	163.44M
Investing Cash Flow	0.00	-13.50M	-2.35M	17.13M	50.57M	-199.51M
Financing Cash Flow	0.00	-103.94M	-104.99M	-1.61M	-1.62M	-3.83M

Wakamoto Pharmaceutical Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 298.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4512, the sentiment is Negative. The current price of 298 is below the 20-day moving average (MA) of 305.05, below the 50-day MA of 301.90, and above the 200-day MA of 283.55, indicating a neutral trend. The MACD of -1.56 indicates Positive momentum. The RSI at 41.38 is Neutral, neither overbought nor oversold. The STOCH value of 28.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4512.

Wakamoto Pharmaceutical Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4524	78 Outperform	9.07B	19.55	4.50%	2.47%	-0.09%	-29.95%
4539	70 Outperform	5.85B	14.70	1.53%	3.09%	5.18%	0.00%
4538	58 Neutral	18.87B	-5.31	7.11%	3.81%	8.71%	-325.91%
4512	52 Neutral	¥10.41B	159.96		1.00%	4.00%	-933.04%
4582	51 Neutral	6.93B	-1.41	0.00%	―	-50.88%	-22.14%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%